BR112022020007A2 - Uso terapêutico de pleuromutilinas - Google Patents

Uso terapêutico de pleuromutilinas

Info

Publication number
BR112022020007A2
BR112022020007A2 BR112022020007A BR112022020007A BR112022020007A2 BR 112022020007 A2 BR112022020007 A2 BR 112022020007A2 BR 112022020007 A BR112022020007 A BR 112022020007A BR 112022020007 A BR112022020007 A BR 112022020007A BR 112022020007 A2 BR112022020007 A2 BR 112022020007A2
Authority
BR
Brazil
Prior art keywords
alkyl
cycloalkyl
atom
nitrogen
pleuromutilins
Prior art date
Application number
BR112022020007A
Other languages
English (en)
Portuguese (pt)
Inventor
Hafner Michael
Paukner Susanne
Wicha Wolfgang
Riedl Rosemarie
IVEZIC-SCHOENFELD Zrinka
Original Assignee
Nabriva Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH
Publication of BR112022020007A2 publication Critical patent/BR112022020007A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112022020007A 2020-04-17 2021-04-16 Uso terapêutico de pleuromutilinas BR112022020007A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
EP20170072 2020-04-17
EP20183292 2020-06-30
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Publications (1)

Publication Number Publication Date
BR112022020007A2 true BR112022020007A2 (pt) 2022-11-22

Family

ID=75801547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020007A BR112022020007A2 (pt) 2020-04-17 2021-04-16 Uso terapêutico de pleuromutilinas

Country Status (9)

Country Link
US (1) US20230174472A1 (https=)
EP (1) EP4135682A1 (https=)
JP (2) JP2023522644A (https=)
CN (1) CN115443131A (https=)
BR (1) BR112022020007A2 (https=)
CA (1) CA3180535A1 (https=)
IL (1) IL297268A (https=)
TW (1) TW202203908A (https=)
WO (1) WO2021209174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134844A1 (en) 2022-02-09 2025-05-01 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
KR102656841B1 (ko) 2015-06-17 2024-04-12 나브리바 테라퓨틱스 게엠베하 레파뮬린의 주사가능한 약제학적 제형
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Also Published As

Publication number Publication date
CA3180535A1 (en) 2021-10-21
JP2023522644A (ja) 2023-05-31
IL297268A (en) 2022-12-01
WO2021209174A1 (en) 2021-10-21
EP4135682A1 (en) 2023-02-22
TW202203908A (zh) 2022-02-01
US20230174472A1 (en) 2023-06-08
CN115443131A (zh) 2022-12-06
JP2026041886A (ja) 2026-03-10

Similar Documents

Publication Publication Date Title
BRPI0809023B8 (pt) derivados de pleuromutilina, seus usos, e composições farmacêuticas
BR112022020007A2 (pt) Uso terapêutico de pleuromutilinas
BR112021021718A2 (pt) Moduladores de thr-ss e métodos de uso dos mesmos
KR950007853A (ko) 종양 치료 방법
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
AR044543A1 (es) Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa
BR0307268A (pt) Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
MX9301525A (es) Esteriodes substituidos en la posicion 17 y composicion farmaceutica que los contiene.
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
BR112013000094A2 (pt) composição dental, kit de peças e uso dos mesmos
ATE69055T1 (de) 19,11beta-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate.
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
BR112022014889A2 (pt) Composto de sulfonamida ou sulfinamida possuindo efeito de indução de degradação da proteína brd4 e uso farmacêutico do mesmo
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
AR111176A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
JPS5598179A (en) Novel arylether*its manufacture and drug containing same for treating allergic disease
AR067454A1 (es) Derivados de indano- amina, su preparacion y uso como medicamentos
AR127497A1 (es) Derivados de piridazin-3(2h)-ona
BR112021018169A2 (pt) Composto para o controle de diabetes de felinos
PE20241186A1 (es) Compuestos de cd73
SE8004744L (sv) Nya tripeptidamider, som inverkar pa det centrala nervsystemet, jemte sett for deras framstellning
SE7701187L (sv) Nya piperazinderivat och sett att framstella desamma
AR018675A1 (es) Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento.
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]